

# INTREPID Alliance Antiviral Clinical Development Landscape: Overview of Priority Viral Families\*

As of November 16, 2023, the 61 clinical phase and approved antiviral compounds fall into 9 of 12 viral families with greatest risk of pandemic potential.

<b>Viral Family</b>	<b>Adenoviridae</b>	<b>Arenaviridae</b>	<b>Coronaviridae</b>	<b>Filoviridae</b>	<b>Flaviridae</b>	<b>Hantaviridae</b>
<b>Indication</b>	Human Adenovirus A-G	Lassa Fever Chapare hemorrhagic fever	SARS-CoV-2	Ebola	Dengue Japanese encephalitis	—
<b>Viral Family</b>	<b>Nairoviridae</b>	<b>Orthomyxoviridae</b>	<b>Paramyxoviridae</b>	<b>Peribunyaviridae</b>	<b>Picornaviridae</b>	<b>Togaviridae</b>
<b>Indication</b>	Crimean Congo hemorrhagic fever	Influenza	Hendra virus	—	Rhinovirus Polio	—


\*As of November 16, 2023



INTREPID ALLIANCE  
INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

Interested  
in engaging  
with us?

For more information, contact  
[nina@intrepidalliance.org](mailto:nina@intrepidalliance.org).

 [intrepidalliance.org](https://intrepidalliance.org)

 [linkedin.com/company/intrepid-alliance](https://linkedin.com/company/intrepid-alliance)